Definium Therapeutics (DFTX)
NASDAQ:DFTX
DFTX Stock Chart & Stats
$17.88
-$0.97(-11.96%)
At close: 4:00 PM EST
$17.88
-$0.97(-11.96%)
Day’s Range― - ―
52-Week Range$4.70 - $19.67
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.56M
Market Cap
$1.78B
Enterprise Value$1.52B
Total Cash (Recent Filing)$411.59M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.59
Next Earnings
May 07, 2026EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding99,698,130
10 Day Avg. Volume1,666,896
30 Day Avg. Volume1,564,734
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)3.60
Price to Sales (P/S)0.00
P/FCF Ratio-9.09
Enterprise Value/Market Cap0.86
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.98
Forecast
1Y Price Target
$37.27Price Target Upside108.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-1.94
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentMultiple late-stage readouts for lead asset DT120 could generate pivotal data that enable a regulatory submission if results are supportive.
Financial ResourcesStrong cash position is expected to fund operations through multiple pivotal trials, lowering the chance of near-term financing pressure.
Trial ExecutionA completed blinded sample-size reassessment in the VOYAGE generalized anxiety trial found no need to increase enrollment, reducing execution risk and improving trial reliability.
Bears Say
Market Expectations And ValuationRecent share price gains appear driven by expectations around trial readouts, leaving the stock vulnerable to sharp moves if clinical results disappoint.
Regulatory And Clinical RiskThe drug's chemical relation to a tightly controlled substance raises unique regulatory and clinical risks that could complicate development and approval.
Timeline UncertaintyA revised timeline for a key trial topline readout increases uncertainty around upcoming clinical milestones and could alter investor expectations.
Definium Therapeutics News
DFTX FAQ
What was Definium Therapeutics’s price range in the past 12 months?
Definium Therapeutics lowest stock price was $4.70 and its highest was $19.67 in the past 12 months.
What is Definium Therapeutics’s market cap?
Definium Therapeutics’s market cap is $1.78B.
When is Definium Therapeutics’s upcoming earnings report date?
Definium Therapeutics’s upcoming earnings report date is May 07, 2026 which is in 39 days.
How were Definium Therapeutics’s earnings last quarter?
Definium Therapeutics released its earnings results on Feb 26, 2026. The company reported -$0.51 earnings per share for the quarter, missing the consensus estimate of -$0.484 by -$0.026.
Is Definium Therapeutics overvalued?
According to Wall Street analysts Definium Therapeutics’s price is currently Undervalued.
Does Definium Therapeutics pay dividends?
Definium Therapeutics does not currently pay dividends.
What is Definium Therapeutics’s EPS estimate?
Definium Therapeutics’s EPS estimate is -0.48.
How many shares outstanding does Definium Therapeutics have?
Definium Therapeutics has 99,698,130 shares outstanding.
What happened to Definium Therapeutics’s price movement after its last earnings report?
Definium Therapeutics reported an EPS of -$0.51 in its last earnings report, missing expectations of -$0.484. Following the earnings report the stock price went up 0.925%.
Which hedge fund is a major shareholder of Definium Therapeutics?
Currently, no hedge funds are holding shares in DFTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Definium Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.27 (108.45% Upside)
$37.27 (108.45% Upside)
Blogger Sentiment
Bullish
DFTX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 4.0%
Last 30 Days ▲ 4.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
178.07%
12-Months-Change
Fundamentals
Return on Equity
-84.39%
Trailing 12-Months
Asset Growth
45.66%
Trailing 12-Months
Company Description
Definium Therapeutics
Definium Therapeutics, Inc. is a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
DFTX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized clear operational and clinical progress: multiple pivotal trials on track with strong enrollment, a favorable blinded SSRE in Voyage that suggests high statistical power, supportive Phase II efficacy data (published in JAMA), an expanded commercial and leadership team, and a strengthened balance sheet with cash runway into 2028. These positives are tempered by substantial y/y expense increases and a larger net loss, dependence on upcoming pivotal results and regulatory interactions, and the absence of disclosed long-term open-label durability data to date. Overall, the company appears well-capitalized and operationally prepared entering a data-rich 2026, but material clinical and regulatory outcomes remain pending.View all DFTX earnings summariesDFTX Stock 12 Month Forecast
Average Price Target
$37.27
▲(108.45% Upside)
Technical Analysis
AnaptysBio
―
Enliven Therapeutics
―
Tyra Bioscience
―
Biohaven Ltd.
―
Inhibrx Biosciences Inc
―
Ownership Overview
2.52% Insiders
2.75% Mutual Funds
7.98% Other Institutional Investors
77.18% Public Companies and Individual Investors